Christoph Zielinski

Austrian physician and oncologist

0members1here now

Ask Genius Site

Christoph Zielinski

Austrian physician and oncologist

0members1here now

Ask Genius Site

Christoph Zielinski is an Austrian physician and cancer researcher. Zielinski is Director of the Clinical Division of Oncology and Chairman of the Department of Medicine I and the Comprehensive Cancer Centre at the Medical University of Vienna. He is also a medical oncologist.

Occupation: physician, oncologist, university teacher
Citizenship: Austria
Born: May 20, 1952

Family

Ricarda Reinischspouse Adam Zielińskifather

Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trialknown for Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?known for Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribersknown for Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients.known for Vaccination with a human high molecular weight melanoma-associated antigen mimotope induces a humoral response inhibiting melanoma cell growth in vitroknown for Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancerknown for Neoplastic stem cells: current concepts and clinical perspectives.known for Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neuknown for University of Viennaemployer Austriacountry of citizenship

Overview

Christoph Zielinski is an Austrian physician and cancer researcher. Zielinski is Director of the Clinical Division of Oncology and Chairman of the Department of Medicine I and the Comprehensive Cancer Centre at the Medical University of Vienna. He is also a medical oncologist.

From Wikipedia (CC BY-SA 4.0).

Born

May 20, 1952

Everything about Christoph Zielinski →

Related journals

Family

Ricarda Reinisch Adam Zieliński

Connected

Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients.Vaccination with a human high molecular weight melanoma-associated antigen mimotope induces a humoral response inhibiting melanoma cell growth in vitro Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer Neoplastic stem cells: current concepts and clinical perspectives.Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu University of Vienna Austria

Live room · 1 here

Be the first in the room — members see you arrive.

Join the room

Christoph Zielinski is an Austrian physician and cancer researcher. Zielinski is Director of the Clinical Division of Oncology and Chairman of the Department of Medicine I and the Comprehensive Cancer Centre at the Medical University of Vienna. He is also a medical oncologist.

Occupation: physician, oncologist, university teacher
Citizenship: Austria
Born: May 20, 1952

Family

Ricarda Reinischspouse Adam Zielińskifather

Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trialknown for Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?known for Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribersknown for Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients.known for Vaccination with a human high molecular weight melanoma-associated antigen mimotope induces a humoral response inhibiting melanoma cell growth in vitroknown for Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancerknown for Neoplastic stem cells: current concepts and clinical perspectives.known for Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neuknown for University of Viennaemployer Austriacountry of citizenship

Related journals

Family

Ricarda Reinisch Adam Zieliński

Connected

Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients.Vaccination with a human high molecular weight melanoma-associated antigen mimotope induces a humoral response inhibiting melanoma cell growth in vitro Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer Neoplastic stem cells: current concepts and clinical perspectives.Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu University of Vienna Austria

Overview

Christoph Zielinski is an Austrian physician and cancer researcher. Zielinski is Director of the Clinical Division of Oncology and Chairman of the Department of Medicine I and the Comprehensive Cancer Centre at the Medical University of Vienna. He is also a medical oncologist.

From Wikipedia (CC BY-SA 4.0).